REG - OptiBiotix Health - Partnership agreement with Morepen for SlimBiome

OptiBiotix HealthAnnouncement

13/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240313:nRSM5803Ga&default-theme=true

RNS Number : 5803G  OptiBiotix Health PLC  13 March 2024

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Partnership agreement with Morepen for SlimBiome® containing finished
products

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skincare,
announces it has signed a partnership agreement with Dr Morepen Ltd
("Morepen") for the sale of SlimBiome® containing products in India under the
Dr Morepen brand. Morepen is a 100% owned subsidiary of Morepen Laboratories
Ltd ("Morepen Laboratories"), an Indian pharmaceutical company listed on the
Indian Stock Exchange.

 

Morepen Laboratories has more than 2,300 employees and sells over 800 products
to over 82 countries. Morepen is a well-known and trusted brand in India,
launched in 2001 to encourage customers to be in charge of their own health
and wellbeing. Morepen has direct access to over 200,000 pharmacies across
India and indirect access to another 300,000 pharmacies. Products will be sold
online, in store, and direct to physicians across India.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this
agreement with Morepen, a well-known and trusted supplier to pharmacies,
physicians, and retail customers across India.  Morepen brings an extensive
sales team with experience of highly differentiated scientific products and
countrywide access to a network of around 500,000 pharmacies across India.
Based on current forecasts, the Directors anticipate this agreement could
contribute in the region of £6-7 million revenue per annum in the next four
to five years."

 

The Directors of the Company are responsible for the release of this
announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                             www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)              Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Peterhouse Capital Limited (Broker)               Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                                   Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements.
These forward-looking statements are not historical facts but rather are based
on the Company's current expectations, estimates, and projections about its
industry; its beliefs; and assumptions. Words such as 'anticipates,'
'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject to known
and unknown risks, uncertainties, and other factors, some of which are beyond
the Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in the
forward-looking statements. The Company cautions security holders and
prospective security holders not to place undue reliance on these
forward-looking statements, which reflect the view of the Company only as of
the date of this announcement. The forward-looking statements made in this
announcement relate only to events as of the date on which the statements are
made. The Company will not undertake any obligation to release publicly any
revisions or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of this
announcement except as required by law or by any appropriate regulatory
authority.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRQLLFFZXLXBBZ